Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 45 of 580 for:    applied AND irritation

A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04006795
Recruitment Status : Not yet recruiting
First Posted : July 3, 2019
Last Update Posted : July 3, 2019
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The purpose of this study is to demonstrate the absence of sensitisation and irritation potential of a product when applied to the skin and exposed to ultraviolet (UV) radiation. Photo-sensitisation potential will primarily be evaluated through a subsequent semi-occluded application and UV exposure (challenge phase) after a 2-week rest period. Photo-irritation potential will primarily be evaluated through the repeated occluded application and UV exposure of the study products over 3 weeks (induction phase).

Condition or disease Intervention/treatment Phase
Skin Care Other: Serum Other: Lotion Other: Cream Other: Normal Saline Not Applicable

Detailed Description:
A single-center, randomised, evaluator (single) blind study in healthy adult participants aged 18 to 65 years with no dermatological disorders to evaluate the cutaneous photo- irritation and photo-sensitisation potential of three cosmetic facial skincare products. During Screening (Visit 1), the participants will sign an informed consent, will undergo dermatological assessment to ensure they have no dermatoses on their dorsum that might impact their safety, Fitzpatrick Phototype of II to IV and colorimetry analysis of their skin type using the Individual Typology Angle, which will be used to estimate minimal erythemal dose (MED). At Visit 2, the eligible participants will undergo MED irradiation where the participant will be administered a series of 6 controlled doses of UV radiation. At Visit 3, the participants will undergo MED determination, where a trained evaluator will evaluate the exposed skin to determine the lowest dose of UV radiation required to induce uniform, unambiguous erythema for signs of visible erythema. Further, the study will progress in 3-phases: Induction phase, Rest Phase and Challenge Phase. The Induction phase (3 weeks: Visit 4 to Visit 18); at visit 4, the area for applying 2 consecutive patches will be designated between the scapula and waistline. A controlled amount (0.02 mL/cm^2) of each study product will be randomly assigned within the patch system of each participant into the appropriate separate cell (3 cells for each of the test products and 1 cell for the saline solution). Every Monday 2 patches will be applied, post 24 hours (Tuesday) the patches will be removed, patch sites will be cleaned, a small amount of test product/ saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeter square UVA radiation with a Schott UG11+WG335 filter (or equivalent) in place, and then with 0.3 MEDs of UVA+UVB radiation (filters UG11+WG320). The sites will be assessed immediately after irradiation and 24 hours post irradiation (Wednesday) and duplicate patches will be re-applied as applied on Monday. Same procedure will be repeated on Thursday as done on Tuesday and on Friday as done on Wednesday. The same process will continue for 3 consecutive weeks. Then there will be 2 weeks of Rest phase; where there will be no product or patch applications. Rest phase is further followed by Challenge phase at week 6 (Visit 19 to Visit 23) where there will be a duplicate parallel series of product applications under semi-occlusive patches to 2 naïve areas on Monday. Post 24 hours (Tuesday) patches will be removed and 1 of the 2 sites will be irradiated similar as done in induction phase. The sites will be assessed immediately post irradiation and after 24 hours (Tuesday), 48 hours (Wednesday) and 72 hours (Thursday) of irradiation. At visit 23, after the challenge phase the final assessments will be performed by the dermatologist.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Other
Official Title: A Photo-irritation and Photo-sensitisation Study in Healthy Subjects for Three Developmental Cosmetic Facial Products
Estimated Study Start Date : July 10, 2019
Estimated Primary Completion Date : September 18, 2019
Estimated Study Completion Date : October 4, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cosmetics

Arm Intervention/treatment
Experimental: Developmental Serum
All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square[mL/cm^2] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
Other: Serum
Participants will be topically applied adhesive patch containing developmental serum

Experimental: Developmental Lotion
All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
Other: Lotion
Participants will be topically applied adhesive patch containing developmental lotion

Experimental: Developmental Cream
All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
Other: Cream
Participants will be topically applied adhesive patch containing developmental cream

Placebo Comparator: Negative Control
All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
Other: Normal Saline
Participants will be topically applied adhesive patch containing normal saline




Primary Outcome Measures :
  1. Proportion of Participants With Photo-initiated Potential Sensitization Reaction [ Time Frame: Day 40 ]
    Scoring of patch test reactions will be performed by blind evaluator as per International Contact Dermatitis Research Group grading'- to +++', where '-' negative reaction, '?+' doubtful reaction; faint erythema only, '+' weak(non-vesicular) positive reaction; erythema, infiltration and possibly papules, '++' strong(vesicular) positive reaction; erythema, infiltration, papules and vesicles, '+++' extreme positive reaction; bullous reaction, intense erythema and infiltration, coalescing vesicles. Any positive reaction (a score of '+' or greater): considered potential sensitization(PS) based upon dermatologist discretion and will further be classified as potential photo-initiated if a) a positive reaction occur only at ultraviolet (UV) exposed site, or b)occur at both sites(UV and non-UV) with the maximum score at the UV exposed site being higher than the maximum score at the non-UV exposed site. Proportion of participants with photo-initiated PS will be reported in this outcome measure.


Secondary Outcome Measures :
  1. Proportion of Participants With a Photo-initiated Reaction (Score of '+' or Greater) Which is not Considered Potential Sensitisation Reaction [ Time Frame: Day 40 ]
    Scoring of patch test reactions will be performed by blind evaluator as per International Contact Dermatitis Research Group grading'- to +++', where '-' negative reaction, '?+' doubtful reaction; faint erythema only, '+' weak (non-vesicular) positive reaction; erythema, infiltration and possibly papules, '++' strong (vesicular) positive reaction; erythema, infiltration, papules and vesicles, '+++' extreme positive reaction; bullous reaction, intense erythema and infiltration, coalescing vesicles. Any positive reaction (a score of '+' or greater) will be classified as photo-initiated if a) a positive reaction occurs only at UV exposed site, or b) occur at both sites (UV and non-UV) with the maximum score at the UV exposed site being higher than the maximum score at the non-UV exposed site. Proportion of participants with any photo-initiated reaction (score of '+' or greater) without potential sensitisation will be reported in this outcome measure.

  2. Proportion of Participants With a Potential Sensitisation Reaction Which is not Considered Photo-initiated [ Time Frame: Day 40 ]
    Scoring of patch test reactions will be performed by blind evaluator as per International Contact Dermatitis Research Group grading'- to +++', where '-' negative reaction, '?+' doubtful reaction; faint erythema only, '+' weak (non-vesicular) positive reaction; erythema, infiltration and possibly papules, '++' strong (vesicular) positive reaction; erythema, infiltration, papules and vesicles, '+++' extreme positive reaction; bullous reaction, intense erythema and infiltration, coalescing vesicles. Any positive reaction (a score of '+' or greater) will be considered as potential sensitization based upon dermatologist discretion and will further be considered as non-photoinitiated if: a positive reaction occurs only at the non-UV exposed site. Proportion of participants with any non-photoinitiated potential sensitisation will be reported in this outcome measure.

  3. Proportion of Participants With a Non-photoinitiated Reaction (Score of '+' or Greater) Which is not Considered Potential Sensitisation Reaction [ Time Frame: Day 40 ]
    Scoring of patch test reactions will be performed by blind evaluator as per International Contact Dermatitis Research Group grading'- to +++', where '-' negative reaction, '?+' doubtful reaction; faint erythema only, '+' weak (non-vesicular) positive reaction; erythema, infiltration and possibly papules, '++' strong (vesicular) positive reaction; erythema, infiltration, papules and vesicles, '+++' extreme positive reaction; bullous reaction, intense erythema and infiltration, coalescing vesicles. Any positive reaction (a score of '+' or greater) will be considered as non-photoinitiated if: a positive reaction occurs only at the non-UV exposed site. Proportion of participants with non-photoinitiated reaction (score of '+' or greater) without potential sensitisation will be reported in this outcome measure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • A participant who is willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon dermal examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  • A participant with Fitzpatrick phototype II to IV.
  • A participant with healthy, intact skin at the proposed test area dorsum (below the shoulder, above the waist), as evaluated by a dermatologist, to ensure participant is free of clinically relevant dermatological conditions.

Exclusion Criteria:

  • A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a GSK CH employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies involving investigational product(s) within 30 Days prior to study entry and/or during study participation.
  • A participant who has participated in other studies including non-medicinal, cosmetic studies within 7 Days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who is pregnant (self-reported).
  • A participant who is breastfeeding.
  • A participant with known or suspected intolerance or hypersensitivity to the study materials/product (or closely related compounds) or any of their stated ingredients, to hypoallergenic tape, or to the cotton patches.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
  • A participant unwilling or unable to comply with the Lifestyle Considerations; a) applying other product to test site, using cosmetics, b) changing dietary habits, c) getting patch test site wet, d) removing the patch, e) wearing tight or restrictive clothing that can remove patch, f) engaging in activities that result in excessive sweating, and g) intentional exposure to artificial ultraviolet light or cosmetic procedures.
  • A participant with current or recent (within last 6 months before the start of the study) history of atopic lesions and/or eczema, psoriasis or skin cancer.
  • A participant with a history of allergic reactions to topical-use products, cosmetics or medications or their ingredients.
  • A participant with any history of significant diseases or medical conditions known to alter skin appearance or physiologic response (e.g. diabetes) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluation of the test site reaction.
  • A participant considered immune-compromised.
  • A participant with active dermatosis (local or disseminated) that might interfere with the results of the study.
  • A Participant with history of diseases aggravated or triggered by ultraviolet radiation.
  • A participant currently using any medication, which in the opinion of the investigator, may affect the evaluation of the investigational product, or place the participant at undue risk (e.g. any photosensitising medication such as tetracycline, thiazides, fluoroquinolones, etc.) within one month prior to inclusion.
  • A participant who has used any of the following topical or systemic medications up to two weeks before the screening visit: immuno-suppressants, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDS), and particular aspirin (>200mg/d), within two weeks prior to inclusion and/or corticosteroids.
  • A participant who has used oral or topical treatment with vitamin A acid and/or its derivatives up to 1 month before the screening visit.
  • A participant who has been vaccinated up to 1 month before the screening visit or is intending to receive a vaccination during their participation in the study.
  • Currently receiving allergy injections or received an allergy injection within 7 days prior to Visit 1 or expects to begin injections during study participation.
  • A participant with any skin marks on the back that might interfere with the evaluation of possible skin reactions (e.g. pigmentation disorders, vascular malformations, scars, tattoos, excessive hair, numerous freckles, open sores, pimples, or cysts).
  • A participant that intends bathing (in the sea or a pool), using a sauna, or partaking in water sports, or activities that lead to intense sweating for the duration of the study.
  • A participant who has used a transcutaneous electrical nerve stimulation (TENS) machine 1 day before the screening visit or intends to use a TENS machine at any point during the study.
  • A participant with history of sensitisation in a previous patch study.
  • A participant with history of abnormal reaction to sun exposure.
  • A participant who had intense sunlight exposure or sun tanning sessions up to 30 days before the screening evaluation.
  • A participant with recent history (within the last 5 years) of alcohol or other substance abuse.
  • A participant who has previously been enrolled in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04006795


Contacts
Layout table for location contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com

Locations
Layout table for location information
Brazil
GSK Investigational Site Not yet recruiting
Sao Paulo, Brazil, 01455-000
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com   
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT04006795     History of Changes
Other Study ID Numbers: 212378
First Posted: July 3, 2019    Key Record Dates
Last Update Posted: July 3, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
Skin Care, Cosmetic Facial Product